Alexis N Pulliam
Overview
Explore the profile of Alexis N Pulliam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
35
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Michalaki E, Pulliam A, Datta Roy P, Dixon J, LaPlaca M
Neurotrauma Rep
. 2025 Feb;
6(1):115-128.
PMID: 39990707
Traumatic brain injury (TBI) is a major health disorder for which there are few treatments. The glymphatic system is the brain's inbuilt lymphatic-like system that is thought to be responsible...
2.
Leontyev D, Pulliam A, Ma X, Gaul D, LaPlaca M, Fernandez F
Front Chem
. 2024 Jun;
12:1394064.
PMID: 38873407
Traumatic brain injury (TBI) is a global public health problem with 50-60 million incidents per year, most of which are considered mild (mTBI) and many of these repetitive (rmTBI). Despite...
3.
Pulliam A, Pybus A, Gaul D, Moore S, Wood L, Fernandez F, et al.
Metabolites
. 2024 Mar;
14(3).
PMID: 38535293
Traumatic brain injury (TBI) is a significant source of disability in the United States and around the world and may lead to long-lasting cognitive deficits and a decreased quality of...
4.
Leontyev D, Pulliam A, Ma X, Gaul D, LaPlaca M, Fernandez F
bioRxiv
. 2024 Feb;
PMID: 38328252
Traumatic brain injury (TBI) is a global public health problem with 50-60 million incidents per year, most of which are considered mild (mTBI) and many of these repetitive (rmTBI). Despite...
5.
Pulliam A, Gier E, Gaul D, Moore S, Fernandez F, LaPlaca M
ACS Chem Neurosci
. 2024 Jan;
15(2):300-314.
PMID: 38179922
Traumatic brain injury (TBI) is a major health concern in the United States and globally, contributing to disability and long-term neurological problems. Lipid dysregulation after TBI is underexplored, and a...
6.
Gier E, Pulliam A, Gaul D, Moore S, LaPlaca M, Fernandez F
Metabolites
. 2022 Feb;
12(2).
PMID: 35208224
Traumatic brain injury (TBI) poses a major health challenge, with tens of millions of new cases reported globally every year. Brain damage resulting from TBI can vary significantly due to...
7.
Berman A, Damrath J, Hatch J, Pulliam A, Powell K, Hinton M, et al.
Connect Tissue Res
. 2021 Jan;
63(1):3-15.
PMID: 33427519
Raloxifene (RAL) is a selective estrogen receptor modulator (SERM) that has previously been shown to cause acellular benefits to bone tissue. Due to these improvements, RAL was combined with targeted...
8.
Powell K, Brown A, Skaggs C, Pulliam A, Berman A, Deosthale P, et al.
Bone Rep
. 2020 Feb;
12:100246.
PMID: 32016137
Raloxifene (RAL) is an FDA-approved drug used to treat osteoporosis in postmenopausal women. RAL suppresses bone loss primarily through its role as a selective estrogen receptor modulator (SERM). This hormonal...